All News
Filgotinib Bows Out of the RA Race in the USA
Gilead Sciences Inc announced yesterday that it has decided not to pursue the an rheumatoid arthritis (RA) indicatin for its once daily oral JAK inhibitor, filgotinib (also named Jyseleca).
Read ArticleConsensus Recommendations on JAK Inhibitor Use
A steering committee and task force was convened to develop recommendations for the use of Janus kinase (JAK) inhibitors in the treatment of immune-mediated inflammatory diseases (IMID).
Read ArticleUpadacitinib Effective in Biologic Refractory Psoriatic Arthritis
The SELECT-PsA 2 trial was presented at the ACR meeting and recently published in Annals of Rheumatic Disease, shows that psoriatic arthritis (PsA) patients who have failed at least one biologic DMARD, did respond well to upadacitinib.
Read ArticleDr. John Cush RheumNow ( View Tweet)
Links:
Vaccination with Shingrix: Does it work for patients on JAKi?
Dr. Jeffrey Curtis examines abstracts #1997 and #0452 presented at the ACR 2020 annual meeting.
Read ArticleLinks:
Links:
ACR20 - Day 4 Report
Here are my highlights from day four, Monday, of the ACR 2020 Convergence.
Vaccine Immunogenicity with Tofacitinib
Read ArticleLinks:
Dr. John Cush RheumNow ( View Tweet)
Tofacitinib for Ankylosing Spondylitis
Investigations on the efficacy and safety of JAK inhibitors as a therapeutic option in the management of AS are increasing.
Read ArticleLinks:
Mrinalini Dey DrMiniDey ( View Tweet)
k dao KDAO2011 ( View Tweet)
Jeffrey Curtis RADoctor ( View Tweet)
Upadacitinib vs. Adalimumab vs. PBO in PsA Phase 3 RCT ⬇️MSK symptoms, PsO, function, pain, fatigue, rads progression in UPA *⃣UPA15 non-inferior to ADA for ACR20, UPA30 superior *⃣Similar VTE in all arms @RheumNow #ACR20 Abs#2026 https://t.co/OHzIjXKqAu
Mrinalini Dey DrMiniDey ( View Tweet)